KR20120033699A - Cosmetic components comprised of the rubiadin having anti-allergy activity - Google Patents

Abstract

PURPOSE: A cosmetic composition containing rubiadin is provided to suppress beta-hexosaminidase secreation and caspase-1 expression and to treat atopic dermatitis. CONSTITUTION: A cosmetic composition for preventing and relieving allergy contains 0.00001-30 wt% of rubiadin as an active ingredient, isolated from adventitious roots of Morinda citrifolia L. The cosmetic composition contains 0.01-1.0 wt% of dipotassium glycyrrhizinate, 0.3-10.0 wt% of 1,3-butylene glycol, and 0.01-1.0 wt% of sodium hyaluronate.

Description

Rubiadin having anti-allergic effect and cosmetic composition comprising the same {Cosmetic components comprised of the rubiadin having anti-allergy activity}

The present invention relates to a rubiviadin having an activity against allergies and a cosmetic composition effective in preventing and alleviating allergies including the same. More specifically, by inhibiting the expression of β-hexosaminidase and histamine during degranulation of rat mast cells, and by inhibiting caspase-1 expression during allergic reaction, rubidine extraction method and anti-allergic cosmetic composition using rubidine are useful. It is about.

Allergy is a biochemical phenomenon that shows a specific and modified response to a foreign body. It is a type of sensitization caused by immune imbalance. It is a response to a specific antigen called allergen. The reaction in which an IgE-class antibody specific to the antigen is bound to mast cells or basophils is induced. to be. When allergen-specific IgE antibodies are made, these antibodies bind to Fc receptors on the surface of mast cells or basophils, and when allergens bind, these cells are activated to activate various bioactive substances (cytokines, prostaglandins). , Leukotrienes, histamine, bradykinin, tryptase, etc.) are secreted to induce changes such as vasodilation, increased permeability of blood vessels, smooth muscle contraction, and inflammatory responses. These responses can occur locally or systemically, depending on the type and amount of mediator these cells produce. Diseases include allergic atopic dermatitis, systemic allergies, allergic rhinitis, asthma, food allergies, and skin allergies.

In detail about allergic reactions, histamine is formed by decarboxylation of histidine by L-histidine dicarboxylase and stored in granules in mast cells or basophils. When allergens bind to mast cells or basophils and allergic reactions begin, the cells are degranulated to release histamine, and β-hexosaminidase is also secreted. This enzymatic activity could be used as a measure of mast cell degranulation and used in experiments.

In addition, the degree of inhibition of expression of caspase-1, which is activated during an allergic reaction to stimulants, was measured.

On the other hand, atopy occurs mainly in infancy and is also called febrile fever, and mainly occurs as the content of ceramides in the stratum corneum decreases. As atopic dermatitis is deteriorated in the stratum corneum, the skin dries up, resulting in a large amount of dead skin, and as the skin barrier is deteriorated, irritant substances such as antigenic proteins, which are difficult to invade in normal skin, enter the stratum corneum. The back develops easily and shows severe pruritus. Therefore, more than 90% of atopic patients are infected with Staphylococcus aureus, which may be caused by scratching because the patient cannot tolerate itching, but recent reports suggest that the toxins of this bacterium stimulate the body's immune system and cause allergies. It is said to make atopic dermatitis worse.

Allergic diseases were 0.9 per 100,000 people in 1979, but the number of allergic diseases increased to 1.4 in 1998, about 55.6%. Therefore, the importance of disease alleviation and prevention became more important. Existing therapeutic agents can be divided into steroidal anti-inflammatory drugs or nonsteroidal anti-inflammatory drugs and antihistamines or anti-leukotrienes. The former have a strong immune lubricating agent, so they can have a temporary calming effect in a short period of time, but they can be mild, such as nausea. From side effects to serious side effects such as growth inhibition and osteoporosis, there are many problems with long-term use. The latter may show a temporary relief, but there are side effects such as drowsiness and dizziness, which limits its use. Therefore, there is a need for a substance derived from a natural extract with little side effects and high antiallergic activity.

Noni (Morinda citrifolia) is a tree that grows deeply rooted in volcanic soil, ranging from small bushes to trees up to 9 meters high. It is widely used as a traditional medicine for folk remedies, along with aloe vera, kelp and papaya parknogenol in Polynesia, South Pacific Islands, Taiti, Hawaii, Malaysia and China of volcanic soils. Or Pagokcheon (巴戟 天) is known.

Examples of the preceding invention using noni, a cosmetic composition containing a noni supercritical extract (Korean Patent 10-09555720000), a skin anti-aging cosmetic composition (No. 10-08442750000), tissue containing Noni extract as an active ingredient Cosmetic composition comprising the cultured noni cultured cell extract and a method for producing the tissue cultured noni cultured cell extract (Korean Patent Publication No. 10-2010-0102437), skin function regenerating cosmetics (JO 2005-145945), skin or hair cosmetics ( JP 2004-035454). However, it was not used for anti-allergic purposes, and there was a limit to simply a composition containing noni extract.

Accordingly, the present inventors have confirmed that rubidine (Rubiadin) contained in noni has an antiallergic effect, and completed the present invention characterized by containing rubidine.

Therefore, an object of the present invention is to inhibit the expression of histamine, β-hexosaminidase produced during the allergic reaction, and to suppress caspase-1 expression generated during the allergic reaction, thereby preparing rubidine and anti-allergic cosmetic compositions using the same. . Furthermore, the anti-allergic cosmetic composition is intended to prevent the deterioration of atopy, and in addition to the ceramide as a component to give an atopic improvement effect.

The present invention provides a cosmetic composition that is effective in the prevention and alleviation of allergies containing rubidin (Rubiadin) as an active ingredient.

In addition to rubidine, noni is composed of geronine, progeronine, serotonin, damnacantal, nordamnacantal, anthrokinose, carrenoid, mordine, terpene, vegetable sterol, cytosterol, azaline, asolic acid, caproic acid, glucopyranose, Serotonin precursor, isoleucine, valine, and includes more than 60 kinds of natural ingredients, the present invention relates to a cosmetic composition comprising a rubidine (Rubiadin) of which is isolated as an active ingredient.

Rubidine, an active ingredient of the composition of the present invention, is synthesized or separated from noni (Morinda citrifolia) involuntary root. The methylene chloride layer and hexane layer were separated, and each layer was separated by high performance liquid chromatography (HPLC). In addition, the aliquot was analyzed by UPLC to confirm that it was rubidine. The content of specific preparative and analytical conditions is as showing in Example 1.

In the present invention, noni extract can be obtained by using a variety of extraction solvents and extraction methods known in the art. Preferred examples of such extraction solvents include water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), acetone, ethyl acetate, chloroform, 1,3-butylene glycol, butyl acetate, and the like. There is a single solvent selected from the group or a mixed solvent of two or more thereof.

The present invention is a cosmetic composition for the prevention and alleviation of allergic cosmetics containing the rubidine, characterized in that the rubidine is contained in 0.00001 to 30% by weight, particularly preferably 0.0025 to 0.01% by weight. Essence cosmetics, nourishing cosmetics, essence, nutrition cream, body cream, baby lotion, baby cream was prepared.

Allergy prevention and alleviation of the present invention is characterized by inhibiting histamine release, inhibiting β-hexosaminidase expression and suppressing caspase-1 expression generated during an allergic reaction. Therefore, in order to prove the anti-allergic effect of rubidine, an experiment was conducted to confirm the inhibitory effect of rubiviadin β-hexosaminidase expression in Example 4 and the inhibitory effect of rubiviadin caspase-1 expression. The isolated rubidine is measured for anti-allergic efficacy evaluation on rat basophilic leukemia (RBL-2H3) and hunman mast cell (HMC-1) cells to provide a cosmetic composition comprising the same.

In Example 2, the basic suitability of rubiviadin as a raw material for cosmetics was tested through toxicological experiments on cells. When fibroblasts were cultured, rubiviadin did not show toxicity to cells at concentrations of 2.5 µg / ml or less. To ensure basic safety.

Rubidine has an antioxidant action. SOD converts superoxide ions into oxygen and hydrogen peroxide because superoxide dismutases (SODs) free radical anions that are harmful to cells. It serves to protect cells from toxicity. In almost all cells exposed to oxygen, this SOD antioxidant defense mechanism is important, and some lactic acid bacteria are known to use a different defense mechanism. In Example 3, the anti-oxidant effect was confirmed that rubiviadin exhibited SOD-like activity at 50 µg / ml by measuring the absorbance at 450 nm using a microplate counter, and further confirmed the removal of hydroxyl peroxide as a peroxide. It was.

As an effect on specific anti-allergic effects of rubidine, 1 mg / ml IgE antibody was added to RBL-2H3 (Rat basophilic leukemia) cells in Example 4, followed by culturing, and 50 μl of the supernatant was centrifuged. 50 μl each was reacted to measure the results at 405 nm. The release of β-hexosaminidase, which is used as a release indicator of histamine, was measured. Confirmed very good. Specific experimental conditions and results are the same as in Example 4.

In addition, the expression level of caspase-1 was measured using a Caspase-1 colormetric assay kit (R & D system) to prove that rubiviain inhibited the expression of caspase-1. 1 expression was inhibited, Western blotting was confirmed to have a very high effect on the inhibition of the expression of pro-caspase-1, it was also confirmed that the expression of active caspase-1. Specific experimental conditions and results are the same as in Example 5.

Therefore, the cosmetic composition having the anti-allergic effect of the present invention is a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence It can be prepared in various formulations, such as nutritional essences, packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions or body cleansers. In Formulation Examples 1 to 7 as examples of products to which the composition can be added, specific compositions for softening cream, nourishing cream, essence, nourishing cream, body cream, baby lotion, and baby cream are shown.

To the cosmetic of the present invention, in addition to using the rubidine as an active ingredient, other ingredients usually formulated in the cosmetic may be blended as necessary.

Meanwhile, in the present invention, Formulations 6 and 7 include ceramide as a component in addition to rubidine, and not only prevent atopic deterioration due to allergy due to the anti-allergic effect of the rubidine, ceramide is a skin barrier analog and restores the skin barrier. It is used in, it is more effective in improving atopic symptoms by providing excellent skin moisturizing effect by promoting the exfoliation effect of the skin at 1.0 to 3.0% by weight relative to the total weight of the composition.

In the present invention, in the softening agent water, essence, night cream, and body cream further comprising 1,3 butylene glycol, 1,3 butylene glycol is a kind of polymer moisturizer of polyhydric alcohol, which is relatively less irritating and less sticky. , It has an antimicrobial effect. 1,3 butylene glycol is the most effective antimicrobial when compared to glycerol, solitol, and propylene glycol.

Rubidine has an antiallergic effect by inhibiting the expression of β-hexosaminidase, histamine production enzymes and histamine release and caspase-1, and furthermore, it is effective in removing hydroxide peroxide as an antioxidant and peroxide. Therefore, the cosmetic composition including the same may have an effect on prevention and alleviation of allergies. Furthermore, the addition of ceramide is effective in improving atopic symptoms through the moisturizing effect.

1 shows the structural formula of rubidine.
Figure 2 shows the experimental results of caspase-1 expression measurement in Example 5.
Figure 3 shows the result of developing with an X-ray film in Western blotting in Example 5.

Example  One. From Noni Rubidine  detach

The methylene chloride layer and hexane layer, which showed antiallergic effect, were separated by Prep-LC (LC 8A, Shimadzu). 10 mg of the solvent fraction was dissolved in 10 ml of methanol and filtered through a 0.2um syringe filter to inject 5 ml. Prep-LC preparative conditions were ODS C18 (300 x 250mm, Shimadzu) column and 100% methanol considering mobile phase concentration. The flow rate was 15 ml / min. The hexane and methylene chlorine layers were separated by HPLC, and the separation conditions are shown in Table 1 below.

Parameter Condition HPLC Prominance  20 A ( Shimadzu , Japan ) Mobile phase MeOH  : water  = 70: 30 Column ODS  C18 (4.6 x 250 mm ) Wavelength 280 nm Injection vol . 20 ul Oven temp . 30 ℃ Flow rate One ml Of min

HPLC condition for analysis of fraction .

Components preparated by HPLC were analyzed by UPLC (20A, Shimadzu). Analytical conditions were 70% methanol, column VP-ODS (3 x 75mm, Shimadzu), flow rate 0.1ml / min, analysis wavelength was 280nm. The molecular weight and fragments of the fractionated FRH2, FRM3 were identified by GC / MS / MS (320MS, Varian). GC / MS / MS analysis conditions were performed using a DB5 (30m x 0.25mm id x 0.25um) column. The temperature of the inlet was 230 ° C., the flow rate was 1 ml / min, and the column oven temperature was maintained at 80 ° C. for 2 min. The EI-MS was analyzed at transfer line temperature of 210 ℃, source temperature of 180 ℃ and 70eV.

FRH2 and FRM3 having the largest peaks were identified as rubiadin by HPLC, GC / MS / MS, IT-TOF, and UV / VIS analysis. The structure of Rubiadin is shown in FIG.

The rubiadine required for the experiment used Chromadex (USA).

Example  2. Cytotoxicity Test

2-1. Experiment method

In order to examine the cytotoxicity against rubidine according to the present invention, human fibroblast cells were injected at a concentration of 5x10 ⁴ cells / ml in a 200 well aliquot in a 96well plate at 37 ° C. in a CO ₂ incubator for 1 day. Incubated. At this time, the medium was used as IMDM (lscove's Modified Eagle Medium, Gibco) containing 10% bovine serum and 1% antibiotics. After incubation was replaced with IMDM medium without bovine serum and antibiotics, samples were added by concentration, and then incubated for 45 hours under the same culture conditions. After incubation, 5 mg / mL MTT (Thiazolyl Blue Tetrazolium Bromide) reagent is added and incubated for 3 hours under the same conditions. Thereafter, the culture medium was removed, and 150 μl of DMSO (Dimetyl sulfoxide) was added thereto, followed by shaking for 10 minutes. The results were measured at 570 nm of a micro plate reader, and the values are shown in Table 2 below.

2-2. Experiment result

Rubiadin Sample (µg / mL) Control group 0.1 0.5 One 2.5 5 Cell proliferation (%) 100 118 99.6 108.4 89.5 78.7

As shown in Table 1, the cell deposition rate was increased at 0.1 μg / ml and 1 μg / ml of rubidine, and it was confirmed that rubivia did not show toxicity at a concentration of 2.5 μg / ml or less.

Example  3. Rubidine  Antioxidative effect

3-1. Superoxide dismutase (SOD) -like activity measurement

3-1-1. Experiment method

SOD-like activity was measured by adding 20 μl of 100 ppm of sample solution to each extract and adding 200 μl of WST working solution in a superoxide dismutase kit (SST assay kit-WST). Then, 20 µl of the enzyme working solution was added and mixed, and then reacted in an incubator at 37 ° C. for 20 minutes, and the absorbance was measured at 450 nm using a microplate counter. Superoxide dismutase (1,000 units) was used, and the superoxide dismutase-like activity was expressed as the absorbance decrease rate of the sample solution added and non-added.

3-1-2. Experiment result

Sample (µg / mL) 50 25 10 Rubiadin 29.1% 5.4% 0.8%

As shown in Table 3 above, it was confirmed that rubiviadin exhibited superoxide decutase-like activity at a concentration of 50 μg / ml or more.

3-2. Hydrogen Peroxide Removal Effect

3-2-1. Experiment method

Hydrogen peroxide removal effect experiment was performed by adding 20 μl of rubidine, 10 mM hydrogen peroxide 20 μl, 0.1 M phosphate buffer (pH 5) in 96well plate and reacting for 5 minutes at 37 ° C., followed by 1.25 mM ABTS. 30 μl of 1 U / ml peroxidase was added and reacted at 37 ° C. for 10 minutes, and the absorbance was measured at 405 nm.

3-2-2. Experiment result

Sample (µg / mL) 50 25 10 Rubiadin 50.3% 31.4% 14.5%

As shown in Table 4, rubivia was confirmed to exhibit hydrogen peroxide removal activity at a concentration of 50 ㎍ / ㎖ or more.

3-3. Hydroxyl radical removal effect

3-3-1. Experiment method

Hydroxyl radical scavenging effect experiment was carried out in 200well of rubidine, 10mM ferrous sulfate 200l, 10mM identiate 200l, 10mM deoxyribose 200l, 0.1M phosphate buffer (pH 7.4) 1200l, 10mM in 96well plate Add 200 μl hydrogen peroxide and react for 4 hours at 37 ° C., add 1 ml of 2.8% TCA and 1% TBA, and boil for 10 minutes. The absorbance was measured at 532 nm by centrifugation.

3-3-2. Experiment result

Sample (µg / mL) 50 25 10 Rubiadin 41.5% 20.0% 6.8%

As shown in Table 5, it was confirmed that rubidine shows hydroxyl radical scavenging activity at a concentration of 50 µg / ml or more.

Example  4. Rubidine  β- hexosaminidase  Inhibitory effect

4-1. Experiment method

RBL-2H3 (Rat basophilic leukemia) cells were counted to 5x10 ⁵ cells / ml using Modified eagle medium (MEM) medium containing 10% bovine serum and 1% antibiotics. IgE antibody is added and aliquoted into a 24-well culture plate, followed by incubation for 24 hours in a 37C, CO ₂ incubator. After incubation, the culture medium was removed and washed twice with 1 ml of PBS solution. After 260 µl of the releasing buffer and the sample were added to each concentration, the culture solution was incubated for 10 minutes under the same conditions. Add BC to this and incubate for 1 hour under the same conditions. After incubation, take 200µl each, centrifuge at 300LP, for 5 minutes, take 50µl of the supernatant, transfer to 96-well culture plate, add 50µl of substrate and react for 30 minutes under the same conditions, then add 150µl of 100mM carbonate buffer. Shake for 5 minutes and measure the result on a microplate counter 405 nm.

4-2. Experiment result

Concentration (μg / ml) Rubidine (%) Control group 66.9 12.5 64.1 25 84.0 50 76.8

As shown in Table 6, it was found that the rubidine has an excellent inhibitory effect on β-hexosaminidase release. This indicates that rubiviadin, which is an active ingredient of the present invention, may inhibit degranulation of mast cells and inhibit allergy induction.

(The control group used ketotifen fumarate. Ketotifen fumarate is used as an antihistamine.)

Example  5. Rubidine caspase -1 inhibitory effect

5-1-1. Caspase-1 colormetric assay

Human mast cell (HMC-1) cells were counted to 6x10 ⁶ cells / ml using lscove's Modified Eagle Medium (IMDM) medium containing 10% bovine serum and 1% antibiotics. 37 ℃, CO ₂ after dispensing It was stabilized for 10 minutes in the incubator. After the incubation treatment with rubidine and incubated for 1 hour under the same conditions. After treatment with the stimulant and incubated at the same conditions for 2 hours, the protein is separated from the cells using Lysis buffer. Caspase-1 expression was measured using a Caspase-1 colormetric assay kit (R & D system).

5-1-2. Experiment result

As shown in FIG. 2, rubivia inhibited caspase-1 expression at a concentration of 10 μg / ml.

5-2-1. Western blotting

Experiments were performed with the protein isolated from 5-1-1. Electrophoresis using 12% SDS-PAGE and transfer to PVDF membrane. After 1 hour bloking in tris buffer containing 5% skim milk, caspase-1 and β-actin antibodies were reacted. Horseraldehyde peroxidase (HRP) conjugated antibody was added and reacted for 1 to 3 minutes using an enhanced chemiliminescent (ECL, amersham, UK) kit and developed with X-ray film.

5-2-2. result

As shown in Figure 3, rubidine was confirmed to inhibit the expression of pro-caspase-1 and active caspase-1 at a concentration of 10 ㎍ / ㎖, in particular showed a high effect on the inhibition of pro-caspase-1 expression.

6. Prescription Example

An example of a cosmetic composition formulation containing rubidine of the present invention as an active ingredient will be described, but the present invention is not intended to be limited thereto but only to be described in detail.

Prescription Example  6-1

Prescription Examples of Soft Cosmetics in Cosmetics Containing Rubidine Table 7 is as follows.

ingredient Content (% by weight) Rubidine 0.001 Polyoxyethylene Cured Castor Oil 0.5 Glycine 3.0 Dipotassium glycylizate 0.1 1,3-butylene glycol 3.0 Sodium hyaluronate 0.1 ethanol 5.0 Antioxidant 0.1 Triethanolamine 0.1 EDTA 0.1 antiseptic Quantity Purified water Balance

Prescription Example  6-2

Table 8 shows a prescription example of nutritional longevity in cosmetics containing rubidine.

ingredient Content (% by weight) Rubidine 0.001 glycerin 7.0 Sorbitan stearate sucrose cocoate 2.0 Mineral oil 4.0 Trioctanoine 1.0 Stearic acid 1.0 Glyceryl stearate 0.5 Sorbitan monostearate 1.0 Dimethicone 0.5 Antioxidant 0.3 Triethanolamine 0.1 Carbomer 0.2 EDTA 0.1 antiseptic Quantity Purified water Balance

Prescription Example  6-3

Formulation examples of the essence in the cosmetic containing rubidine is shown in Table 9.

ingredient Content (% by weight) Rubidine 0.001 glycerin 5.0 1,3-butylene glycol 2.0 Polyethylene glycol 2.0 Carbomer 1.0 Sodium hyaluronate 0.1 Glycine 3.0 Polyacrylamide 2.0 Hydroxyethyl Cellulose 0.2 ethanol 3.0 Antioxidant 0.3 Triethanolamine 0.1 Polyoxyethylene Cured Castor Oil 1.0 EDTA 0.1 antiseptic Quantity Purified water Balance

Prescription Example  6-4

Table 10 shows an example of the prescription of nutrition cream in the cosmetic containing rubidine.

ingredient Content (% by weight) Rubidine 0.001 1,3-butylene glycol 3.0 glycerin 3.0 Hydrogenated Lecithin 1.0 Octyldodecanol 3.0 Trioctanoine 2.0 Stearic acid 1.5 Cetostearyl alcohol 2.0 Polysorbate 60 1.5 Sorbitan sesquioleate 2.0 Dimethicone 3.0 Antioxidant 0.3 Xanthan Gum 0.2 Triethanolamine 0.1 EDTA 0.1 antiseptic Quantity Purified water Balance

Prescription Example  6-5

Table 11 shows an example of the prescription of body cream among the cosmetics containing rubidine.

ingredient Content (% by weight) Rubidine 0.001 glycerin 7.0 1,3-butylene glycol 3.0 Squalene 3.0 Dimethicone 3.0 Sodium hyaluronate 0.1 Glycine 2.0 Polyacrylamide 5.0 Antioxidant 0.3 Triethanolamine 0.1 EDTA 0.1 antiseptic Quantity Purified water Balance

Prescription Example  6-6

Formulation examples of the baby lotion among the cosmetics containing rubidine are shown in Table 12.

ingredient Content (% by weight) Rubidine 0.001 glycerin 5.0 Panthenol 4.0 Ceramide 0.1 Phytosing 0.1 Cetearyl Alcohol 0.5 Phospholipids 1.0 Stearic acid 0.5 Camellia oil 7.0 Shea Butter 1.0 Sodium Copolyacrylate (5% dispersion) 10.0 Compound preservative 0.5 Purified water Balance

Prescription Example  6-7

Formulation examples of the baby cream in the cosmetic containing rubidine are shown in Table 13.

ingredient Content (% by weight) Rubidine 0.001 glycerin 5.0 Panthenol 4.0 Ceramide 0.5 Phytosing 0.5 Cetearyl Alcohol 1.0 Phospholipids 3.0 Stearic acid 1.5 Camellia oil 16.0 Shea Butter 2.0 Sodium Copolyacrylate (5% dispersion) 15.0 Compound preservative 0.5 Purified water Balance

Claims (10)

Rubiadin (Rubiadin) as an active ingredient cosmetic composition for allergy prevention and alleviation, characterized in that it comprises 0.00001 to 30% by weight relative to the total weight of the composition.
The method of claim 1,
The rubidine is a cosmetic composition for allergy prevention and alleviation, characterized in that it is isolated from noni root muscle.
The method of claim 1,
The rubiadine (Rubiadin) is a cosmetic composition for allergy prevention and alleviation, characterized in that it comprises 0.0025 to 0.01% by weight relative to the total weight of the cosmetic composition.
The method according to claim 1 or 3,
The cosmetic is a main ingredient in addition to rubidine,
0.01-1.0 wt% dipotassium glycylizate;
0.3-10.0 wt% of 1,3-butylene glycol;
Softening longevity composition for allergy prevention and alleviation, characterized in that it comprises 0.01 to 1.0% by weight sodium hyaluronate.
The method according to claim 1 or 3,
The cosmetic is a main ingredient in addition to rubidine,
Sorbitan stearate sucrose cocoate 0.2-8.0 wt%;
0.01 to 5.0 weight percent of trioctanoine;
0.01 to 5.0 wt% stearic acid;
Nutritional longevity composition for allergy prevention and alleviation, comprising sorbitan monostearate 0.1 to 5.0% by weight.
The method according to claim 1 or 3,
The cosmetic is a main ingredient in addition to rubidine,
0.2-10.0 wt% of 1,3-butylene glycol;
0.2-10.0 weight percent polyethylene glycol;
Carbomer 0.1 to 5.0% by weight; Essence composition for allergy prevention and alleviation, comprising a.
The method according to claim 1 or 3,
The cosmetic is a main ingredient in addition to rubidine,
0.3-15.0 wt.% 1,3-butylene glycol;
0.1 to 4.0 wt% hydrogenated lecithin;
0.2-8.0 wt% trioctanoin;
Nutritional cream composition for allergy prevention and alleviation, comprising 0.1 to 7.0% by weight of stearic acid.
The method according to claim 1 or 3,
The cosmetic is a main ingredient in addition to rubidine,
0.3-15.0 wt.% 1,3-butylene glycol;
0.01-1.0 wt% sodium hyaluronate;
Polyacrylamide 0.05 to 20.0% by weight; Body cream composition for allergy prevention and alleviation comprising a.
The method according to claim 1 or 3,
The cosmetic is a main ingredient in addition to rubidine,
0.01 to 5.0 weight percent of ceramide;
0.01 to 5.0 weight percent of phytostingosine;
Phospholipids from 0.1 to 4.0 weight percent;
Stearic acid 0.05 to 2.5% by weight; Baby lotion or baby cream composition for allergy prevention and alleviation comprising a.
(a) preparing a Noni extract with respect to the dried Noni root root using water or a solvent selected from the group consisting of alcohol, acetone, chloroform and 1,3-butylene glycol;
(b) separating the methylene chloride layer and the hexane layer from the Noni root extract with Prep-LC;
(c) separating the hexane layer and the methylene chlorine layer separated by step (b) by HPLC respectively;
(d) analyzing the components separated by HPLC in step (c) by UPLC to identify rubidine;
A method for separating rubidine from noni abscess solvent extract, characterized in that it comprises a.

Images